3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors prevent the progression of renal dysfunction in Japanese hypertensive patients

Geriatrics and Gerontology International

Volumn 10, Issue 3, 2010, Pages 219-224

  Kuwabara, Masanori ^a   Kubo, Toru ^b   Bando, Kanji ^a   Hirakawa, Yoko ^a   Kitaoka, Hiroaki ^a   Nishinaga, Masanori ^b   Doi, Yoshinori L ^b  

^a Tosa Municipal Hospital   (Japan)

^b KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

Chronic kidney disease; Hypertension; Statins

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; JAPANESE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; COMPLICATION; JAPAN; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; JAPAN; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES;

EID: 77954361857     PISSN: 14441586     EISSN: 14470594     Source Type: Journal    
DOI: 10.1111/j.1447-0594.2010.00584.x     Document Type: Article

References (22)

1. Jones CA, McQuillan GM, Kusek JW. Serum creatinine levels in the US population: third National Health and Neutrition Examination Survey. Am J Kidney Dis 1998, 32:992-999.
2. Coresh J, Selvin E, Stevens LA. Prevalence of chronic kidney disease in the United States. JAMA 2007, 298:2038-2047.
3. Imai E, Horio M, Yamagata K. Slower decline of glomerular filtration rate in the Japanese general population: a longitudinal 10-year follow-up study. Hypertens Res 2008, 31:433-441.
4. Ninomiya T, Kiyohara Y. Chronic kidney disease and other disease. 1. Cardiovascular disease. Nippon Naika Gakkai Zasshi 2007, 96:887-893. In Japanese
5. Brosius FC, Hostetter TH, Kelepouris E. Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease. Circulation 2006, 114:1083-1087.
6. Tonelli M, Wiebe N, Culleton B. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006, 17:2034-2047.
7. Ninomiya T, Kiyohara Y, Kubo M. Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study. Kidney Int 2005, 68:228-236.
8. Mcclellan WM, Flanders WD. Risk factors for progressive chronic kidney disease. J Am Soc Nephrol 2003, 14:S65-S70.
9. Ninomiya T, Kiyohara Y, Kubo M. Metabolic syndrome and CKD in a general Japanese population: the Hisayama Study. Am J Kidney Dis 2006, 48:383-391.
10. Matsuo K, Inoue T, Node K. Estimated glomerular filtration rate as a predictor of secondary outcomes in Japanese patients with coronary artery disease. J Cardiol 2009, 53:232-239.
11. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
12. Nakamura H, Arakawa K, Itakura H. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006, 368:1155-1163.
13. Sever PS, Dahlof B, Poulter NR. ASCOT investigators. Prevention of coronary and stroke events with atrovastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outocomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised co trolled trial. Lancet 2003, 361:1149-1158.
14. Shepherd J, Kastelein JJ, Bittner V. TNT Investigators. Intensive lipid lowering with atrovastatin in patients with coronary heart disease and chronic kidney disease: the TNT Study. J Am Coll Cardiol 2008, 51:1448-1454.
15. Tonelli M, Isles C, Curhan GC. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 2004, 110:1557-1563.
16. Lee TM, Su SF, Tsai CH. Effect of pravastatin on proteinuria in patients with well-controlled hypertension. Hypertension 2002, 40:67-73.
17. Athyros VG, Mikhailidis DP, Papageorgiou AA. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. a subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004, 57:728-734.
18. Tonelli M, Isles C, Craven T. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 2005, 112:171-178.
19. Shepherd J, Kastelein JJ, Bittner V. Treating to New Targets Investigators. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) Study. Clin J Am Soc Nephrol 2007, 2:1131-1139.
20. Imai E, Horio M, Iseki K. Prevalence of chronic kidney disease in Japanese general population predicted by MDRD equation modified by a Japanese coefficient. Clin Exp Nephrol 2007, 11:156-163.
21. Keane WF. The role of lipids in renal disease: future challenges. Kidney Int 2000, 57:S27-S31.
22. Kasiske BL, O'Donnell MP, Kim Y, Keane WF. Treatment of hyperlipidemia in chronic progressive renal disease. Curr Opin Nephrol Hypertens 1993, 2:602-608.